文献速递眼底病与葡萄膜炎

持续抑制VEGF治疗视网膜/脉络膜血管性疾病

Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases.
PubMed 文献 · Prog Retin Eye Res · 2020-11-25

新生血管性年龄相关性黄斑变性(NVAMD)是最常见的脉络膜血管疾病,糖尿病视网膜病变(DR)和视网膜静脉阻塞(RVO)是最常见的视网膜血管疾病。缺氧通过稳定缺氧诱导因子-1增加VEGF产生,高VEGF导致血管通透性增加、新生血管形成,并在DR和RVO中促使视网膜血管关闭加重缺氧形成正反馈。临床试验显示频繁眼内注射VEGF中和蛋白在NVAMD、DR或RVO患者中视觉结局优异,但临床实践中注射频率大幅降低且视觉结局令人失望。本文讨论提供持续VEGF抑制的新方法的原理、临床前和早期临床结果。

要点

  • 缺氧稳定HIF-1增加VEGF产生,高VEGF驱动血管通透性、新生血管及血管关闭的正反馈。
  • 选择性抑制VEGF可逆转这些疾病过程中的大部分病理改变。
  • 临床试验中频繁眼内注射VEGF中和蛋白视觉结局优异,但临床实践注射频率降低致视觉结局失望。

核心结论

  • 持续抑制VEGF的新方法将革新这些常见视网膜/脉络膜血管疾病的管理。

研究设计与样本

  • 本文为综述,讨论持续抑制VEGF新方法的原理、临床前和早期临床结果。

主要发现

  • 缺氧稳定HIF-1增加VEGF产生,高VEGF导致血管通透性增加和新生血管形成。
  • 在DR和RVO中高VEGF促使视网膜血管关闭加重缺氧形成正反馈。
  • 选择性抑制VEGF可逆转这些疾病过程中的大部分病理改变。
  • 临床试验中频繁眼内注射VEGF中和蛋白在NVAMD、DR或RVO患者中视觉结局优异。
  • 临床实践中注射频率大幅降低且视觉结局令人失望。

临床怎么用

  • 持续抑制VEGF的新方法有望革新NVAMD、DR和RVO的管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neovascular age-related macular degeneration (NVAMD) is the most prevalent choroidal vascular disease, and diabetic retinopathy (DR) and retinal vein occlusion (RVO) are the most prevalent retinal vascular diseases. In each of these, hypoxia plays a central role by stabilizing hypoxia-inducible factor-1 which increases production of vascular endothelial growth factor (VEGF) and other hypoxia-regulated gene products. High VEGF causes excessive vascular permeability, neovascularization, and in DR and RVO, promotes closure of retinal vessels exacerbating hypoxia and creating a positive feedback loop. Hence once VEGF expression is elevated it tends to remain elevated and drives disease progression. While other hypoxia-regulated gene products also contribute to pathology in these disease processes, it is remarkable how much pathology is reversed by selective inhibition of VEGF. Clinical trials have demonstrated outstanding visual outcomes in patients with NVAMD, DR, or RVO from frequent intraocular injections of VEGF-neutralizing proteins, but for a variety of reasons injection frequency has been substantially less in clinical practice and visual outcomes are disappointing. Herein we discuss the rationale, preclinical, and early clinical results of new approaches that provide sustained suppression of VEGF. These approaches will revolutionize the management of these prevalent retinal/choroidal vascular diseases.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Campochiaro PA, Akhlaq A. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Prog Retin Eye Res. 2020. PMID: 33248215. doi:10.1016/j.preteyeres.2020.100921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。